What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, 3
What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, […]
RheumNow
RheumNow
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMb
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMb https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
AI Scribes Found their Favorite Doctors
AI Scribes Found their Favorite Doctors tammytilley@gm… Sun, 10/26/2025 – 20:53 Education/ACR/EULAR General Rheumatology Dr. Aurelie Najm discusses abstract 0189,
Next Generation T-Cell Engager: The Future
Next Generation T-Cell Engager: The Future tammytilley@gm… Sun, 10/26/2025 – 19:29 Education/ACR/EULAR Novel Rx Dr. Alfred Kim reviews abstract 0001
RheumNow
High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in
High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg john+RNV2@john…
RheumNow
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Ad
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Ad https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john…
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE tammytilley@gm… Sun, 10/26/2025 – 19:09 Lupus Novel Rx Steroids Dr. Sheila
RheumNow
ACR25 Best Abstracts – Day 1
ACR25 Best Abstracts – Day 1 jjcush@gmail.com Sun, 10/26/2025 – 19:00
RheumNow
Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel bette
Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel bette
RheumNow
Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ?
Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ? https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg john+RNV2@john… Sun, 10/26/2025
RheumNow
What are the RFs for progression of Pso to PsA? 🔸PsO disease severity – 3.2x risk —>PsA 🔸Phenotype – nail in
What are the RFs for progression of Pso to PsA? 🔸PsO disease severity – 3.2x risk —>PsA 🔸Phenotype – nail
RheumNow
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWAC
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWAC https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
Google News
How Investors Are Reacting To Spyre Therapeutics (SYRE) Phase 1 Data on SPY072’s …
We’ll explore how SPY072’s differentiated dosing profile could influence Spyre Therapeutics’ place in the competitive rheumatology pipeline. Rare …
RheumNow
ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m
ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Sun, 10/26/2025 – 18:01 RheumNow Dr. John Cush ACR2025 Day 1 RECAP https://t.co/zARgu7vx3m
Rheumatology
CAR T-cell therapy improves skin, lung function in SSc
CHICAGO — CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic
Google News
Large language models ‘substantially’ improved medical trainees’ diagnostic accuracy
… study because diagnostic reasoning in rheumatology is particularly complex due to the multisystem nature of rheumatic diseases and their
JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis
(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective
RheumNow
Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months
Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun,
STOP RA Cellular & Serologic Predictors
STOP RA Cellular & Serologic Predictors tammytilley@gm… Sun, 10/26/2025 – 16:49 Rheumatoid Arthritis Labs/Biomarkers Dr. Jack Cush discusses abstract 0774,
Google News
ACR 2025 Convergence: Updates on New SLE Guidelines | Lupus Foundation of America
… rheumatology therapies. The new guidelines include three strong recommendations: Taper prednisone dose to <5 mg daily within six months,;
Rheumatology
Study: LLMs improved medical students’ diagnostic accuracy
CHICAGO — Large language models, when used alongside human clinical judgement, “substantially” improved diagnostic accuracy among a cohort of medical
Google News
Study Finds Opioid Prescribing Prevalent Among Older Adults With Rheumatic Disease
Patients prescribed opioids to relieve pain associated with rheumatic disease may not always experience a benefit as it has been
RheumNow
New Gout Therapies Show Promise in Phase III Trials
New Gout Therapies Show Promise in Phase III Trials tammytilley@gm… Sun, 10/26/2025 – 16:06
RheumNow
Upadacitinib in GCA doesn’t just affect IL-6, it alters IFNg, known to be important in vascular change in GCA. If UPA i
Upadacitinib in GCA doesn’t just affect IL-6, it alters IFNg, known to be important in vascular change in GCA. If
RheumNow
A closer look in skin toxicity of GCs in RMDs GC Toxicity Index, LONG TOX prospective cohort Frequent: -Easy bruising 3
A closer look in skin toxicity of GCs in RMDs GC Toxicity Index, LONG TOX prospective cohort Frequent: -Easy bruising
RheumNow
Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy… …but <5mg/kg associated w/1.8
Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy… …but <5mg/kg associated w/1.8 https://pbs.twimg.com/profile_images/1982460526815764480/EQEuBdmh_normal.jpg john+RNV2@john… Sun, 10/26/2025 –